Illumina Q3 Earnings Call Highlights

Key Points

• Illumina exceeded third-quarter guidance, reporting $1.17 billion in revenue, a 25% non-GAAP operating margin and $1.44 in adjusted EPS. The company raised its full-year revenue, margin and EPS outlook.
• Clinical sequencing demand drove NovaSeq X momentum: Illumina placed more than 80 instruments during the quarter and about 360 over the past four quarters, while clinical sequencing consumables grew 14% organically.
• The company expects BioInsight, AI-driven biological data initiatives and a recovering China business to support future growth, with management reiterating its path toward high-single-digit growth over the longer term.

Illumina NASDAQ: ILMN reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year revenue, operating-margin and earnings outlook, while executives said they remain on track toward longer-term growth targets.

Management said financial measures discussed on the call excluded the impact of tariff refunds recognized during the quarter. According to Head of Investor Relations Conor McNamara, the refunds positively affected GAAP and non-GAAP operating income, margins and earnings per share, while negatively affecting revenue.

Third-Quarter Results and Updated Outlook

Third-quarter revenue totaled $1.17 billion, representing 4.7% year-over-year rest-of-world organic growth. Currency and acquired revenue contributed just under three percentage points to reported growth, Chief Financial Officer Ankur Dhingra said.

Non-GAAP operating margin was 25%, 100 basis points above the company’s guidance, while diluted earnings per share were $1.44, up 7% from a year earlier. Gross margin was 69.4%, an increase of 20 basis points year over year.

• Sequencing consumables revenue was $792 million, up 6% year over year and up 5% on a rest-of-world organic basis.
• Sequencing instruments revenue was $106 million, down 2% on a rest-of-world organic basis, as higher NovaSeq X placements were offset by weaker sales in Europe, the Middle East and Latin America.
• Sequencing service and other revenue was $158 million, up 8% on a rest-of-world organic basis.
• Microarrays and other revenue was $110 million, up 2% organically in rest-of-world markets, including performance from SomaLogic revenue that exceeded the company’s initial deal model.

Illumina generated $419 million in operating cash flow and $378 million in free cash flow during the quarter. It repurchased $9 million in stock and ended the quarter with about $1.8 billion remaining under its share repurchase authorizations. Cash equivalents and short-term investments totaled approximately $1.34 billion, while total debt was $1.79 billion.

The company raised its 2026 revenue outlook by $30 million at the midpoint to a range of $4.64 billion to $4.66 billion. Illumina continues to expect rest-of-world organic growth of more than 5% for the year, mid-single-digit organic growth in sequencing consumables, and low-double-digit instrument growth.

Illumina now expects full-year operating margin of about 23.6% and diluted EPS of $5.40 to $5.45, up $0.08 at the midpoint from prior guidance. For the fourth quarter, the company projected revenue of $1.22 billion to $1.24 billion, rest-of-world organic growth of approximately 4.5%, operating margin of about 25%, and EPS of $1.51 to $1.56.

Clinical Demand Drives NovaSeq X Placements

Chief Executive Officer Jacob Thaysen said the company placed more than 80 NovaSeq X instruments in the quarter, bringing placements over the past four quarters to about 360. He said the total exceeded placements in the platform’s first year after launch.

“Customer demand for the NovaSeq X platform remains at very high levels,” Thaysen said, attributing demand to broader adoption of sequencing-based diagnostics and increasingly sequencing-intensive assays.

Clinical sequencing consumables growth in rest-of-world markets was 14% in the third quarter, while research and applied sequencing consumables declined 6%. Illumina maintained its expectation for mid-teens clinical consumables growth in 2026 and mid- to high-single-digit declines in research and applied consumables.

Dhingra said approximately 84% of high-throughput volume and 60% of high-throughput revenue are now on NovaSeq X. The transition is largely complete in research and applied markets, where 90% or more of volume has been on the X platform for each of the last five quarters. In clinical markets, 78% of volume is on NovaSeq X, with conversion expected to reach 80% to 85% in coming quarters.

The company expects year-over-year pricing headwinds from the X transition to be lower in 2027 than in 2026. It also plans to stop presenting its quarterly X-transition price-and-volume chart after its fourth-quarter 2026 earnings presentation, saying it is becoming less useful as conversion nears completion.

During the question-and-answer session, Thaysen said the recent level of NovaSeq X demand did not reflect pull-forward activity. He pointed to clinical capacity expansion, new assays and future platform innovation as factors supporting demand. Dhingra added that operating-lease and reagent-rental arrangements are seeing increased interest among research customers and midsized clinical laboratories, although they have been less prevalent among the company’s largest clinical customers.

BioInsight and AI Data Opportunities

Illumina also highlighted its BioInsight ecosystem, which combines assays, sequencing platforms, software, artificial intelligence models and biological data. The company introduced the BioInsight platform during the quarter and said it includes access to SpliceAI2, an AI model designed to predict how genetic changes affect RNA splicing.

Thaysen said SpliceAI2 identified 17% more disease-relevant splice variants than other splicing models in rare-disease research data sets. He also discussed the company’s Billion Cell Atlas, which is intended to create a standardized, reproducible perturbation data set for biopharmaceutical customers developing AI models for biology.

GSK joined the Billion Cell Atlas consortium during the period, according to Thaysen. Dhingra said the program is converting more backlog into revenue and that the company sees strong pipeline interest. He said BioInsight and related data initiatives should begin to become more visible financially in 2027, with new products and BioInsight expected to contribute to the company’s previously discussed one-to-two-point growth opportunity.

Management said the AI opportunity could include both services for generating large, standardized biological data sets and demand for instruments and consumables from customers that want to augment Illumina-generated data with their own proprietary data.

China and 2027 Framework

Illumina said it returned to year-over-year growth in China during the third quarter, though executives did not provide detailed regional figures on the call. Thaysen said the company remains committed to serving Chinese customers and sees a sizable opportunity in the market, while continuing to work with regulators and assess geopolitical developments.

Looking ahead, executives deferred detailed 2027 guidance until the fourth-quarter earnings call. Thaysen said the company views more than 5% consumables growth as a starting point, supported by the expanding NovaSeq X installed base, clinical demand, multi-omics offerings and emerging AI-related data opportunities. He reiterated that Illumina remains on track toward the high-single-digit growth range outlined as part of its 2024 strategy.

About Illumina (NASDAQ:ILMN)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.